Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Merck & Co., Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-80.9% vs price
Base Case (Median)
-32.2% vs price
Bull Case (75th pct.)
-18.8% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $565.21 | 283.5% | High (40%) |
| PE Comparable | $28.57 | -80.6% | Medium (25%) |
| Growth Trajectory DCF | $27.79 | -81.1% | Medium (20%) |
| Graham Number | $24.47 | -83.4% | Medium (40%) |
| EV/EBITDA | $99.86 | -32.2% | Medium (20%) |
| EV/FCF | $115.50 | -21.6% | Medium (20%) |
| Earnings Power Value | $123.77 | -16.0% | Medium (50%) |
Based on 7 out of 7 methods, MRK appears overvalued at the current price of $147.37. The base case fair value of $99.86 implies 32.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.